Combination immunotherapy: Where do we go from here?

Journal for ImmunoTherapy of Cancer

Dario A. A. Vignali¹  Ana Anderson⁴  Drew M. Pardoll³  Mario Sznol²  Sema Kurtulus⁴  Abigail E. Overacre¹ 

[1]Department of Immunology, University of Pittsburgh, Pittsburgh 15213, PA, USA

[2]Division of Medical Oncology, Yale Comprehensive Cancer Center, Yale University, New Haven 06250, CT, USA

[3]Division of Oncology, Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore 21287, MD, USA

[4]Evergrande Center for Immunologic Diseases and Ann Romney Center for Neurologic Diseases, Brigham and Women’s Hospital and Harvard Medical School, Boston 02115, MA, USA

关键词: Immunology;    Exhaustion;    Therapy;    T cells;    Cancer;    Immunotherapy;   

Others  :  1225062
DOI  :  10.1186/s40425-015-0083-z

 received in 2015-04-29, accepted in 2015-07-23,  发布年份 2015

【 摘 要 】

The remarkable clinical success of cancer immunotherapies targeting the checkpoint receptors CTLA-4 and PD-1 has generated considerable excitement and emboldened efforts to build on this important foundation. Research efforts are now focused on understanding the mechanism of action of these immunotherapies, identifying new inhibitory mechanisms that could be targeted to achieve responses in patients with refractory cancers, and developing approaches that might exhibit efficacy against “immunologically inert” tumors. The outstanding challenges in moving forward are developing reliable strategies for determining which patients will respond optimally to a given immunotherapy, and what combination of immunotherapies and conventional therapies will prove beneficial against each tumor type. These issues were discussed in a one-day workshop at the SITC meeting in November 2014.

【 授权许可】

   
2015 Overacre et al.